Product Description
Mechanisms of Action: ADRA1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Korea | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Kidney Calculi|Ureteral Calculi|Ureterolithiasis|Nephrolithiasis|Lower Urinary Tract Symptoms|Prostatic Hyperplasia
Phase 3: Lower Urinary Tract Symptoms|Pain Unspecified|Prostatic Hyperplasia
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR-IPR-15006185 |
ChiCTR-IPR-15006185 | N/A |
Recruiting |
Overactive Bladder|Ureteral Calculi |
2017-09-30 |
|||
NCT00967772 |
FLV100 | P1 |
Completed |
Healthy Volunteers |
2009-10-01 |
2019-03-19 |
Treatments |
|
NCT01952314 |
SNUBH-URO-2012-03 | P3 |
Completed |
Pain Unspecified |
2015-08-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT01959074 |
SNUH-URO-2012-04 | P3 |
Completed |
Pain Unspecified |
2015-06-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT01203371 |
APS 001/2010 | P3 |
Withdrawn |
Prostatic Hyperplasia|Lower Urinary Tract Symptoms |
2011-09-01 |
2023-02-09 |
Primary Endpoints |
|
NCT02011737 |
SMC2013-08-066 | P4 |
Unknown status |
Kidney Calculi|Ureteral Calculi|Nephrolithiasis|Ureterolithiasis |
2015-02-01 |
2019-03-20 |
Treatments |
|
NCT01922375 |
FLV_BPH_IV-1 | P4 |
Completed |
Prostatic Hyperplasia|Lower Urinary Tract Symptoms |
2012-09-01 |
2024-06-26 |
Primary Endpoints|Treatments |